{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T13:45:10Z","timestamp":1790171110329,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,26]],"date-time":"2021-11-26T00:00:00Z","timestamp":1637884800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["75N93019C00052"],"award-info":[{"award-number":["75N93019C00052"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1TR002378"],"award-info":[{"award-number":["UL1TR002378"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007699","name":"University of Georgia","doi-asserted-by":"publisher","award":["UGA-001"],"award-info":[{"award-number":["UGA-001"]}],"id":[{"id":"10.13039\/100007699","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008065","name":"Georgia Research Alliance","doi-asserted-by":"publisher","award":["GRA-001"],"award-info":[{"award-number":["GRA-001"]}],"id":[{"id":"10.13039\/100008065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.ebiom.2021.103748","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T06:39:04Z","timestamp":1639118344000},"page":"103748","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex"],"prefix":"10.1016","volume":"74","author":[{"given":"Juanjie","family":"Tang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Grubbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youri","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supriya","family":"Ravichandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3553-3320","authenticated-orcid":false,"given":"David","family":"Forgacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hana","family":"Golding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ted M","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0593-7965","authenticated-orcid":false,"given":"Surender","family":"Khurana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6536","key":"10.1016\/j.ebiom.2021.103748_bib0001","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1126\/science.abg4493","article-title":"The emerging plasticity of SARS-CoV-2","volume":"371","author":"McCormick","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103748_bib0002","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.chom.2021.03.008","article-title":"SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera","volume":"29","author":"Kuzmina","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"10292","key":"10.1016\/j.ebiom.2021.103748_bib0003","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1016\/S0140-6736(21)01290-3","article-title":"Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination","volume":"397","author":"Wall","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103748_bib0004","doi-asserted-by":"crossref","first-page":"4196","DOI":"10.1038\/s41467-021-24435-8","article-title":"Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies","volume":"12","author":"Greaney","year":"2021","journal-title":"Nat Commun"},{"issue":"6524","key":"10.1016\/j.ebiom.2021.103748_bib0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1126\/science.371.6524.9","article-title":"Fast-spreading U.K. virus variant raises alarms","volume":"371","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"issue":"6527","key":"10.1016\/j.ebiom.2021.103748_bib0006","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1126\/science.371.6527.329","article-title":"New mutations raise specter of 'immune escape","volume":"371","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"issue":"6525","key":"10.1016\/j.ebiom.2021.103748_bib0007","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1126\/science.371.6525.108","article-title":"Viral evolution may herald new pandemic phase","volume":"371","author":"Kupferschmidt","year":"2021","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.ebiom.2021.103748_bib0008","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nat Med"},{"issue":"10278","key":"10.1016\/j.ebiom.2021.103748_bib0009","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/S0140-6736(21)00370-6","article-title":"SARS-CoV-2 variants and ending the COVID-19 pandemic","volume":"397","author":"Fontanet","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ebiom.2021.103748_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2021.2088","article-title":"SARS-CoV-2 Viral Variants-Tackling a Moving Target","author":"Mascola","year":"2021","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103748_bib0011","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.chom.2021.04.007","article-title":"Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization","volume":"29","author":"Wang","year":"2021","journal-title":"Cell Host Microbe"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103748_bib0012","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMc2106083","article-title":"BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants","volume":"385","author":"Liu","year":"2021","journal-title":"N Engl J Med"},{"issue":"7871","key":"10.1016\/j.ebiom.2021.103748_bib0013","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s41586-021-03693-y","article-title":"BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants","volume":"596","author":"Liu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ebiom.2021.103748_bib0014","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.ebiom.2021.103748_bib0015","doi-asserted-by":"crossref","DOI":"10.1172\/JCI148832","article-title":"SARS-Cov2 variants and convalescent plasma: reality, fallacies, and opportunities","author":"Casadevall","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2021.103748_bib0016","article-title":"Increased resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 to antibody neutralization","author":"Ho","year":"2021","journal-title":"Res Sq"},{"issue":"7857","key":"10.1016\/j.ebiom.2021.103748_bib0017","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","article-title":"Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7","volume":"593","author":"Wang","year":"2021","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.ebiom.2021.103748_bib0018","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJMc2102179","article-title":"Serum neutralizing activity elicited by mRNA-1273 vaccine","volume":"384","author":"Wu","year":"2021","journal-title":"N Engl J Med"},{"issue":"600","key":"10.1016\/j.ebiom.2021.103748_bib0019","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abi9915","article-title":"Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection","volume":"13","author":"Greaney","year":"2021","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ebiom.2021.103748_bib0020","doi-asserted-by":"crossref","DOI":"10.1126\/science.abg9175","article-title":"mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection","author":"Stamatatos","year":"2021","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103748_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2021.05.041","article-title":"Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status","volume":"27","author":"Eyre","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.ebiom.2021.103748_bib0022","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/s41591-021-01325-6","article-title":"Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2","volume":"27","author":"Ebinger","year":"2021","journal-title":"Nature Med"},{"key":"10.1016\/j.ebiom.2021.103748_bib0023","doi-asserted-by":"crossref","DOI":"10.1126\/science.abh1282","article-title":"Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose","author":"Reynolds","year":"2021","journal-title":"Science"},{"issue":"7864","key":"10.1016\/j.ebiom.2021.103748_bib0024","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/s41586-021-03594-0","article-title":"Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses","volume":"594","author":"Saunders","year":"2021","journal-title":"Nature"},{"issue":"85","key":"10.1016\/j.ebiom.2021.103748_bib0025","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3002336","article-title":"MF59 adjuvant enhances diversity and affinity of antibody-mediated immune response to pandemic influenza vaccines","volume":"3","author":"Khurana","year":"2011","journal-title":"Sci Transl Med"},{"issue":"550","key":"10.1016\/j.ebiom.2021.103748_bib0026","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3539","article-title":"Antibody signature induced by SARS-CoV-2 spike protein immunogens in rabbits","volume":"12","author":"Ravichandran","year":"2020","journal-title":"Sci Transl Med"},{"issue":"2","key":"10.1016\/j.ebiom.2021.103748_bib0027","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.chom.2020.01.001","article-title":"Longitudinal human antibody repertoire against complete viral proteome from ebola virus survivor reveals protective sites for vaccine design","volume":"27","author":"Khurana","year":"2020","journal-title":"Cell Host Microbe"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103748_bib0028","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/s41467-021-21463-2","article-title":"Antibody affinity maturation and plasma IgA associate with clinical outcome in hospitalized COVID-19 patients","volume":"12","author":"Tang","year":"2021","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.ebiom.2021.103748_bib0029","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf2467","article-title":"Longitudinal antibody repertoire in \"mild\" versus \"severe\" COVID-19 patients reveals immune markers associated with disease severity and resolution","volume":"7","author":"Ravichandran","year":"2021","journal-title":"Sci Adv"},{"key":"10.1016\/j.ebiom.2021.103748_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103006","article-title":"Epitope diversity of SARS-CoV-2 hyperimmune intravenous human immunoglobulins and neutralization of variants of concern","author":"Tang","year":"2021","journal-title":"iScience"},{"issue":"7","key":"10.1016\/j.ebiom.2021.103748_bib0031","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103748_bib0032","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149154","article-title":"One dose of SARS-CoV-2 vaccine exponentially increases antibodies in individuals who have recovered from symptomatic COVID-19","volume":"131","author":"Levi","year":"2021","journal-title":"J Clin Invest"},{"issue":"58","key":"10.1016\/j.ebiom.2021.103748_bib0033","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103748_bib0034","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/infdis\/jiab300","article-title":"Marked increase in avidity of SARS-CoV-2 antibodies 7-8 months after infection is not diminished in old age","volume":"224","author":"Pichler","year":"2021","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.ebiom.2021.103748_bib0035","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/j.cell.2021.01.050","article-title":"Maturation and persistence of the anti-SARS-CoV-2 memory B cell response","volume":"184","author":"Sokal","year":"2021","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ebiom.2021.103748_bib0036","doi-asserted-by":"crossref","DOI":"10.1172\/JCI149150","article-title":"First-dose mRNA vaccination is sufficient to reactivate immunological memory to SARS-CoV-2 in subjects who have recovered from COVID-19","volume":"131","author":"Mazzoni","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ebiom.2021.103748_bib0037","doi-asserted-by":"crossref","DOI":"10.1126\/science.abm0829","article-title":"mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern","author":"Goel","year":"2021","journal-title":"Science"},{"issue":"48","key":"10.1016\/j.ebiom.2021.103748_bib0038","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1016\/j.vaccine.2014.09.049","article-title":"H5 N-terminal beta sheet promotes oligomerization of H7-HA1 that induces better antibody affinity maturation and enhanced protection against H7N7 and H7N9 viruses compared to inactivated influenza vaccine","volume":"32","author":"Khurana","year":"2014","journal-title":"Vaccine"},{"issue":"22","key":"10.1016\/j.ebiom.2021.103748_bib0039","doi-asserted-by":"crossref","first-page":"12283","DOI":"10.1128\/JVI.01596-12","article-title":"Oligomeric recombinant H5 HA1 vaccine produced in bacteria protects ferrets from homologous and heterologous wild-type H5N1 influenza challenge and controls viral loads better than subunit H5N1 vaccine by eliciting high-affinity antibodies","volume":"86","author":"Verma","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.ebiom.2021.103748_bib0040","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/s41467-019-09914-3","article-title":"Differential human antibody repertoires following Zika infection and the implications for serodiagnostics and disease outcome","volume":"10","author":"Ravichandran","year":"2019","journal-title":"Nat Commun"},{"issue":"11","key":"10.1016\/j.ebiom.2021.103748_bib0041","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S2213-2600(19)30253-X","article-title":"Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial","volume":"7","author":"Davey","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.ebiom.2021.103748_bib0042","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002920","article-title":"AID activity in B cells strongly correlates with polyclonal antibody affinity maturation in-vivo following pandemic 2009-H1N1 vaccination in humans","volume":"8","author":"Khurana","year":"2012","journal-title":"PLoS Pathog"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421005429?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396421005429?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:39:02Z","timestamp":1764866342000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396421005429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":42,"alternative-id":["S2352396421005429"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103748","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antibody affinity maturation and cross-variant activity following SARS-CoV-2 mRNA vaccination: Impact of prior exposure and sex","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2021.103748","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"103748"}}